Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 4859

Journal of Addiction Research & Therapy received 4859 citations as per Google Scholar report

Journal of Addiction Research & Therapy peer review process verified at publons
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • SafetyLit
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

Roger L Papke

Roger L Papke Roger L Papke Professor Department of Pharmacology & Therapeutics University of Florida College of Medicine
Research Interest

We study the physiology, pharmacology, and biophysics of neurotransmitter receptors with a special emphasis on the function of nicotinic acetylcholine receptors in the brain. These are the receptors which mediate the effects of nicotine on human behavior. We study how these neuronal nicotinic acetylcholine receptors function as ligand-gated ion channels, identifying parts of the molecule which are involved with the binding of neurotransmitter and the conformational change associated with receptor activation. We are also characterizing the selectivity of experimental nicotinic agonists for specific receptor subtypes in the brain. With this understanding we hope to identify the mechanisms through which nicotine-like substances may alleviate some of the learning and memory impairments in animal models of dementia. The ongoing clinical development of new experimental drugs may lead to novel therapeutics for the treatment of Alzheimer’s disease.

Global Speakers in the subject

Global Experts in the subject

Relevant Topics
Top